Chih Hui Lin

Chief Executive Officer en SYNMOSA BIOPHARMA CORPORATION .

Health Technology

Consumer Services

Perfil

Chih Hui Lin is currently the Chairman, President & General Manager at Synmosa Biopharma Corp.
He is also the Chairman at Yu Chiao Co. Ltd., InnoPharmax, Inc., U-Liang Pharmaceutical Co. Ltd., and Intech Biopharm Ltd.
Mr. Lin completed his undergraduate degree at Taipei Medical University.

Cargos activos de Chih Hui Lin

Empresas	Cargo	Inicio
SYNMOSA BIOPHARMA CORPORATION	Chief Executive Officer	25/02/2011
INNOPHARMAX INC.	Chairman	21/03/2008
INTECH BIOPHARM CORPORATION	Chairman	28/10/2010
Yu Chiao Co. Ltd.	Chairman	-
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Chairman	-

Todos los cargos activos de Chih Hui Lin

Formación de Chih Hui Lin.

Taipei Medical University

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Chih Hui Lin.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	3
SYNMOSA BIOPHARMA CORPORATION	Health Technology
INNOPHARMAX INC.	Health Technology
INTECH BIOPHARM CORPORATION	Health Technology

Empresas privadas	2
Yu Chiao Co. Ltd.
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Health Technology